This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Contract research organization Remove Utilities Related Topics
Strategic partnership Ecosystems Collaboration Biotech Biopharmaceuticals Biopharma Biotechnology Life science Government More Related Topics >
article thumbnail

How does your company’s benchmarking performance stack up against the leading precision health companies in the ecosystem?

Frost & Sullivan

FEBRUARY 15, 2024

Utilize this distinctive competitive benchmarking tool to elevate your future growth potential significantly. The Frost Radar™ serves as a powerful analytical tool for conducting a comprehensive ‘Growth Audit’ across various industries, evaluating key companies on essential criteria related to innovation and growth.

Ecosystems 40
Ecosystems Contract research organization Biotech Utilities 40
article thumbnail

Avance Clinical Earns Frost & Sullivan’s 2023 Best Practices Customer Value Leadership Award for Delivering High-quality Clinical Trials Based on Globally Accepted Data

Frost & Sullivan

AUGUST 6, 2023

San Antonio, TX — 7 th Aug, 2023 — Frost & Sullivan recently researched the Asia-Pacific biotechnology contract research organization industry and, based on its findings, recognizes Avance Clinical with the 2023 Customer Value Leadership Award. In addition, the attractive 43.5%

Biotechnology 52
Biotechnology Biotech Contract research organization Biopharmaceuticals 52
article thumbnail

Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?

Frost & Sullivan

MARCH 22, 2024

Growing demand for outsourcing, with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) leading industry growth. Top 10 pharma companies contribute only 4-5% to R&D pipeline; top 25 contribute less than 10%.

Ecosystems 52
Ecosystems Biopharma Biotech Contract research organization 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 93,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024